Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ELCC 2016

13–16 April 2016 | Geneva, Switzerland

ELCC 2016

13–16 April 2016 | Geneva, Switzerland
Phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma 2:15
Phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma
Giorgio Scagliotti • 15 Apr 2016
Phase 1 study of anti-PD-L1 durvalumab plus gefitinib in TKI-naïve patients with EGFR-mutant NSCLC 2:12
Phase 1 study of anti-PD-L1 durvalumab plus gefitinib in TKI-naïve patients with EGFR-mutant NSCLC
Don Gibbons • 15 Apr 2016
Progress in the treatment of ALK-positive non-small cell lung cancer 0:58
Progress in the treatment of ALK-positive non-small cell lung cancer
David Carbone • 15 Apr 2016
CheckMate 171: Phase 2 trial of nivolumab for advanced squamous cell non-small cell lung cancer 0:47
CheckMate 171: Phase 2 trial of nivolumab for advanced squamous cell non-small cell lung cancer
Enriqueta Felip • 15 Apr 2016
ASSESS trial: Blood test for EGFR mutation in advanced non-small cell lung cancer 2:05
ASSESS trial: Blood test for EGFR mutation in advanced non-small cell lung cancer
Blood samples for detecting actionable oncogenic mutations in lung cancer 2:42
Blood samples for detecting actionable oncogenic mutations in lung cancer
Niki Karachaliou • 15 Apr 2016
Targeting PD-1 and PD-L1 for lung cancer therapy 1:57
Targeting PD-1 and PD-L1 for lung cancer therapy
Joseph Paul Eder • 15 Apr 2016
Differences in expression of predictive biomarkers between primary and metastatic NSCLC 4:21
Differences in expression of predictive biomarkers between primary and metastatic NSCLC
Zoran Gatalica • 15 Apr 2016
Phase 2 trial of BI 1482694 (HM61713), third-generation TKI, in T790M-positive NSCLC 2:55
Phase 2 trial of BI 1482694 (HM61713), third-generation TKI, in T790M-positive NSCLC
Giorgio Scagliotti • 15 Apr 2016
Predictive models of tumor response to chemotherapy and radiotherapy in NSCLC 0:43
Predictive models of tumor response to chemotherapy and radiotherapy in NSCLC
Kenneth O'Byrne • 15 Apr 2016
Overcoming molecular mechanisms of resistance to therapies for non-small cell lung cancer 1:07
Overcoming molecular mechanisms of resistance to therapies for non-small cell lung cancer
Enriqueta Felip • 15 Apr 2016
LUX-Lung 7: Phase 2b trial of first-line afatinib versus gefitinib for EGFR mutation-positive NSCLC 2:14
LUX-Lung 7: Phase 2b trial of first-line afatinib versus gefitinib for EGFR mutation-positive NSCLC
Kenneth O'Byrne • 15 Apr 2016
Clinical trial designs and ongoing trials in immunotherapy for lung cancer 1:47
Clinical trial designs and ongoing trials in immunotherapy for lung cancer
David Carbone • 15 Apr 2016
Blood tests for identifying and monitoring ALK-positive non-small cell lung cancer 1:02
Blood tests for identifying and monitoring ALK-positive non-small cell lung cancer
Niki Karachaliou • 15 Apr 2016
Phase 1b trial of CRS-207 with chemotherapy for malignant pleural mesothelioma 1:34
Phase 1b trial of CRS-207 with chemotherapy for malignant pleural mesothelioma
David Carbone • 15 Apr 2016
Continuing therapeutic progress in lung cancer 1:17
Continuing therapeutic progress in lung cancer
Niki Karachaliou • 13 Apr 2016
The content of VJOncology is intended for healthcare professionals